
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
An oral PCSK9 inhibitor for hypercholesterolemia and a once-weekly basal insulin for type 2 diabetes were among the FDA approvals with direct relevance to primary care in the third quarter of 2026. The decisions also expanded options for ADHD, contraception, influenza prevention, HIV treatment, narcolepsy, and pain relief.






